CG Invites 
Welcome,         Profile    Billing    Logout  
 6 Products   6 Diseases   6 Products   995 Trials   3123 News 


«12...41424344454647484950515253»
  • ||||||||||  camrelizumab (INCSHR1210) / Incyte
    Journal:  Discovery of Imidazoisoindole Derivatives as Highly Potent and Orally Active Indoleamine-2,3-dioxygenase Inhibitors. (Pubmed Central) -  Jun 23, 2019   
    Lead optimization toward improving potency and eliminating CYP inhibition resulted in the discovery of lead compound 25, a highly potent IDO inhibitor with favorable pharmacokinetic properties. In the MC38 xenograft model in hPD-1 transgenic mice, 25 in combination with the anti-PD-1 monoclonal antibody (SHR-1210) achieved a synergistic antitumor effect superior to each single agent.
  • ||||||||||  ivaltinostat IV (CG-745) / CG Invites
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer (clinicaltrials.gov) -  Jun 17, 2019   
    P1/2,  N=24, Active, not recruiting, 
    Randomised controlled trials are needed to further establish the role of immune checkpoint inhibition for nasopharyngeal carcinomas. Recruiting --> Active, not recruiting | N=72 --> 24 | Trial completion date: Jul 2018 --> Aug 2019 | Trial primary completion date: Jul 2018 --> Aug 2019
  • ||||||||||  ivaltinostat IV (CG-745) / CG Invites
    Trial completion date, Trial primary completion date:  Phase 1/2 Study of CG200745 PPA for Myelodysplastic Syndrome (clinicaltrials.gov) -  Jun 14, 2019   
    P1/2,  N=36, Recruiting, 
    Recruiting --> Active, not recruiting | N=72 --> 24 | Trial completion date: Jul 2018 --> Aug 2019 | Trial primary completion date: Jul 2018 --> Aug 2019 Trial completion date: Jul 2018 --> Dec 2019 | Trial primary completion date: Jul 2018 --> Dec 2019
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    New P2 trial:  Apatinib Plus SHR1210 in Advanced Mucosal Melanoma (clinicaltrials.gov) -  Jun 13, 2019   
    P2,  N=40, Recruiting, 
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment change, Trial termination:  SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer (clinicaltrials.gov) -  May 10, 2019   
    P2,  N=12, Terminated, 
    It might add to the expanding literature regarding immune-related dermatologic adverse events. N=135 --> 12 | Recruiting --> Terminated; The study was terminated early due to company decision
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Phase classification, Enrollment change, Trial completion date, Trial primary completion date:  SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov) -  Apr 1, 2019   
    P2,  N=280, Recruiting, 
    Recruiting --> Active, not recruiting Phase classification: P1/2 --> P2 | N=150 --> 280 | Trial completion date: Mar 2020 --> Mar 2025 | Trial primary completion date: Aug 2019 --> Jul 2022
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment open:  ESCORT-1: Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer (clinicaltrials.gov) -  Apr 1, 2019   
    P3,  N=548, Recruiting, 
    Phase classification: P1/2 --> P2 | N=150 --> 280 | Trial completion date: Mar 2020 --> Mar 2025 | Trial primary completion date: Aug 2019 --> Jul 2022 Not yet recruiting --> Recruiting
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Trial primary completion date:  APFAO: Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma (clinicaltrials.gov) -  Mar 18, 2019   
    P2,  N=43, Active, not recruiting, 
    Not yet recruiting --> Recruiting Trial primary completion date: Mar 2018 --> Mar 2019
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    New P2 trial, PD(L)-1 Biomarker, IO biomarker:  Neoadjuvant Immunotherapy for Resectable Gastric Cancer (clinicaltrials.gov) -  Mar 18, 2019   
    P2,  N=30, Not yet recruiting, 
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Trial primary completion date:  APFAO: Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma (clinicaltrials.gov) -  Mar 13, 2019   
    P2,  N=43, Active, not recruiting, 
    Trial primary completion date: Mar 2018 --> Mar 2019 Trial primary completion date: Sep 2018 --> Mar 2018
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Trial completion date, Trial primary completion date:  A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients (clinicaltrials.gov) -  Feb 21, 2019   
    P1,  N=49, Active, not recruiting, 
    Trial primary completion date: Sep 2018 --> Mar 2018 Trial completion date: May 2019 --> Sep 2029 | Trial primary completion date: Nov 2018 --> Mar 2020
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment closed, Trial completion date, Trial primary completion date:  A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects (clinicaltrials.gov) -  Jan 22, 2019   
    P1,  N=99, Active, not recruiting, 
    Trial completion date: May 2019 --> Sep 2029 | Trial primary completion date: Nov 2018 --> Mar 2020 Enrolling by invitation --> Active, not recruiting | Trial completion date: Dec 2017 --> Mar 2019 | Trial primary completion date: Sep 2017 --> Mar 2019
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment closed, Trial completion date, Trial primary completion date:  SHR-1210-III-301-ESC: Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer (clinicaltrials.gov) -  Jan 18, 2019   
    P3,  N=456, Active, not recruiting, 
    Enrolling by invitation --> Active, not recruiting | Trial completion date: Dec 2017 --> Mar 2019 | Trial primary completion date: Sep 2017 --> Mar 2019 Recruiting --> Active, not recruiting | Trial completion date: Mar 2019 --> Jun 2019 | Trial primary completion date: Jun 2018 --> Jun 2019
  • ||||||||||  SHR7390 / Jiangsu Hengrui Pharma, AiRuiKa (camrelizumab) / HLB Bio Group, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
    Trial completion date, Trial primary completion date:  SHR7390-I-102-AST: The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Jan 18, 2019   
    P1,  N=60, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Mar 2019 --> Jun 2019 | Trial primary completion date: Jun 2018 --> Jun 2019 Trial completion date: Jul 2019 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Jul 2019
  • ||||||||||  New P1/2 trial, BRCA Biomarker, PARP Biomarker, PD(L)-1 Biomarker:  FUSCC Refractory TNBC Umbrella (FUTURE) (clinicaltrials.gov) -  Jan 15, 2019   
    P1/2,  N=140, Recruiting,